Figure 1.
Staging scans performed in patients with missed metastatic disease prior to RALP_
| PSA ng/mL | MRI T stage | Bone Scan | CT CAP | Lymph node dissection | Biochemical recurrence | Post-op PSMA PET/CT | |
|---|---|---|---|---|---|---|---|
| Patient 1 | 18.0 | T3a | Negative | Negative | Negative | Yes | Positive |
| Patient 2 | 6.4 | T2c | Negative | Not performed | Not performed | Yes | Negative |
| Patient 3 | 5.3 | T3a | Negative | Not performed | Negative | Yes | Not performed |
| Patient 4 | 5.5 | Not performed | Negative | Negative | Positive | No | n/a |
| Patient 5 | 3.9 | T3a | Negative | Negative | Positive | No | n/a |
| Patient 6 | 4.7 | T3a | Negative | Not performed | Positive | No | n/a |
Patient demographics and staging scans for patients with Gleason 4+3 intermediate risk disease_
| Patient demographics (n=134) | Median (range or %) |
|---|---|
| Age | 72 (45 – 83) |
| PSA (ng/mL) | 7.8 (1.8 – 19.3) |
| Prostate volume (mL) | 40 (10 – 129) |
| Biopsy type | |
| TRUS | 14 (10) |
| Transperineal | 120 (90) |
| MRI prostate (n=130) | |
| PIRADS 2 | 15 (11) |
| PIRADS 3 | 9 (7) |
| PIRADS 4 | 66 (51) |
| PIRADS 5 | 40 (31) |
| MRI T stage | |
| T1 | 8 (6) |
| T2 | 74 (57) |
| T3a | 48 (37) |
| MRI N Stage | |
| N0 | 128 (98) |
| N1 | 2 (2) |
| MRI M stage | |
| M0 | 130 (100) |
| Bone scan (n=124) | |
| NM Bone scan | 121 (98) |
| SPECT CT | 3 (2) |
| CT scan (n=83) | |
| CT chest / abdomen / pelvis | 77 (93) |
| CT Urogram | 4 (5) |
| CTKUB | 1 (1) |
| CT abdomen / pelvis | 1 (1) |
| Both CT & Bone scan (n=77) | 77 (53) |